A newly funded national clinical trial initiative will gather critical evidence to determine the best treatment strategies for older adults with acute myeloid leukemia (AML), an aggressive, fast-moving blood cancer that leaves a substantial proportion of older patients facing uncertainty about whether to proceed to stem cell transplantation or continue non-transplant therapy.